Want to see OPCH full AI Analyst Report?
OPCH Stock Chart & Stats
$23.90
$0.58(2.75%)
At close: 4:00 PM EDT
$23.90
$0.58(2.75%)
Day’s Range― - ―
52-Week Range$18.01 - $36.80
Previous CloseN/A
Volume1.57M
Average Volume (3M)5.53M
Market Cap
$4.67B
Enterprise Value$4.29B
Total Cash (Recent Filing)$193.77M
Total Debt (Recent Filing)$1.27B
Price to Earnings (P/E)23.5
Beta0.54
Next Earnings
Nov 04, 2026EPS Estimate
0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.33
Shares Outstanding149,785,250
10 Day Avg. Volume12,476,305
30 Day Avg. Volume5,534,870
Financial Highlights & Ratios
PEG Ratio6.12
Price to Book (P/B)3.89
Price to Sales (P/S)0.91
P/FCF Ratio23.78
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue0.75
Enterprise Value/Gross Profit4.15
Enterprise Value/Ebitda10.34
Forecast
1Y Price Target
$28.74Price Target Upside20.23% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)1.88
Revenue Forecast (FY)$5.76B
Bulls Say, Bears Say
Bulls Say
Infusion Platform And Clinic ExpansionThe national alternate-site platform is gaining capacity and utilization through clinic expansion, while higher in-clinic activity can deepen clinical integration and improve operating leverage. This supports durable access to chronic and acute infusion demand beyond a single therapy or location.
Strong Cash Generation And ProfitabilityHigh free-cash-flow conversion indicates that reported earnings are translating into cash that can fund technology, clinics, debt service and other strategic priorities. Continued positive operating cash flow provides resilience and supports investment without relying entirely on external financing.
Strategic Support From Acquisition AgreementThe proposed ownership structure could provide additional capital and strategic resources while preserving Option Care as a separately managed operating company. McKesson’s healthcare position and CD&R’s support may help advance technology and growth initiatives over time, subject to approvals.
Bears Say
Chronic Inflammatory Portfolio HeadwindsPressure in the chronic inflammatory portfolio is significant enough to affect both revenue and gross profit, creating a durable near-term drag on the business mix. Recovery depends on replacing lost contribution with growth in other therapies, which may take multiple quarters.
Margin CompressionFalling net margins show that profitability has not kept pace with revenue expansion, limiting the earnings benefit of scale. If mix pressure and operating costs persist, weaker margins could constrain reinvestment, reduce cash available for strategic priorities, and make growth less efficient.
Moderate Leverage Reduces FlexibilityModerate leverage is serviceable but reduces financial flexibility if reimbursement, therapy mix or operating performance deteriorates. Debt obligations can compete with clinic expansion, technology investment and other uses of cash, making balance-sheet discipline important during the transition.
Option Care Health News
OPCH FAQ
What was Option Care Health’s price range in the past 12 months?
Option Care Health lowest stock price was $18.01 and its highest was $36.80 in the past 12 months.
What is Option Care Health’s market cap?
Option Care Health’s market cap is $4.67B.
When is Option Care Health’s upcoming earnings report date?
Option Care Health’s upcoming earnings report date is Nov 04, 2026 which is in 14 days.
How were Option Care Health’s earnings last quarter?
Option Care Health released its earnings results on Jul 29, 2026. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.426 by $0.024.
Is Option Care Health overvalued?
According to Wall Street analysts Option Care Health’s price is currently Undervalued.
Does Option Care Health pay dividends?
Option Care Health does not currently pay dividends.
What is Option Care Health’s EPS estimate?
Option Care Health’s EPS estimate is 0.49.
How many shares outstanding does Option Care Health have?
Option Care Health has 149,785,250 shares outstanding.
What happened to Option Care Health’s price movement after its last earnings report?
Option Care Health reported an EPS of $0.45 in its last earnings report, beating expectations of $0.426. Following the earnings report the stock price went up 6.45%.
Which hedge fund is a major shareholder of Option Care Health?
Currently, no hedge funds are holding shares in OPCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Option Care Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$28.74 (20.23% Upside)
$28.74 (20.23% Upside)
Blogger Sentiment
Bullish
OPCH Sentiment 86%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.38%
12-Months-Change
Fundamentals
Return on Equity
15.83%
Trailing 12-Months
Asset Growth
-0.12%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Option Care Health
Option Care Health, Inc. delivers infusion services to patients in their homes and other non-hospital settings throughout the United States. The company offers a broad spectrum of specialized infusion treatments, including therapies for various infections, management of heart failure, and comprehensive nutritional support (both intravenous and tube feeding) for individuals with acute or chronic conditions such as stroke, cancer, and digestive illnesses. They also provide immunoglobulin infusions for immune system deficiencies and treatments targeting chronic inflammatory disorders like Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Furthermore, Option Care Health assists in managing the progression of neurological conditions such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy. They also administer infusion therapies for bleeding disorders and provide crucial support for women experiencing high-risk pregnancies. Other specialized infusion services encompass pain relief, chemotherapy, and respiratory care. Complementing these medical offerings, the company provides professional nursing services. Option Care Health, Inc. maintains its primary corporate office in Bannockburn, Illinois.
OPCH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balance of meaningful operational and financial positives — including sequential revenue and EBITDA growth, strong cash generation ($184M in Q2), active share repurchases ($150M), clinic expansion, and progress in key portfolios (acute, IG neuro, rare/orphan) — while acknowledging persistent headwinds tied to the CID portfolio that are expected to depress 2026 revenue (~600 bps) and gross profit (~$55M). Management emphasized execution of commercial, technology and cost initiatives to drive sequential improvement through the back half of the year, but several initiatives and new therapy launches carry timing and execution risk.View all OPCH earnings summariesOPCH Stock 12 Month Forecast
Average Price Target
$28.74
▲(20.23% Upside)
Technical Analysis
Addus Homecare
―
Chemed
―
Viemed Healthcare
―
Aveanna Healthcare Holdings
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
1.28% Insiders
38.75% Mutual Funds
1.15% Other Institutional Investors
26.70% Public Companies and
Individual Investors